Cargando…
eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study
BACKGROUND: Shrunken Pore Syndrome (SPS), defined as a reduced ratio between two estimated filtration rates (based on cystatin C and creatinine) is an increasingly recognized risk factor for long-term mortality. Although some patients with other conditions might be erroneously identified as SPS. Our...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500727/ https://www.ncbi.nlm.nih.gov/pubmed/37704948 http://dx.doi.org/10.1186/s12882-023-03315-x |
_version_ | 1785105971358466048 |
---|---|
author | Avotins, Lauris Kroica, Juta Petersons, Aivars Zentina, Dace Kravale, Zaiga Saulite, Anna Racenis, Karlis |
author_facet | Avotins, Lauris Kroica, Juta Petersons, Aivars Zentina, Dace Kravale, Zaiga Saulite, Anna Racenis, Karlis |
author_sort | Avotins, Lauris |
collection | PubMed |
description | BACKGROUND: Shrunken Pore Syndrome (SPS), defined as a reduced ratio between two estimated filtration rates (based on cystatin C and creatinine) is an increasingly recognized risk factor for long-term mortality. Although some patients with other conditions might be erroneously identified as SPS. Our aim was to bring the focus on possible pathophysiologic mechanisms influencing the ratio in the setting of SARS-CoV-2 pneumonia and acute kidney injury. METHODS: A single-centered prospective cohort study was conducted to investigate biomarkers in symptomatic COVID-19 pneumonia patients admitted to a hospital in Latvia. Nineteen biomarkers were measured in blood and three in urine samples. Associations were sought between these biomarkers, chronic diseases and the estimated GFR(cystatinC)/eGFR(creatinine) ratio < 0.6, mortality rates, and acute kidney injury development. Data analysis was performed using SPSS Statistics, with significance set at p < 0.05. RESULTS: We included 59 patients (average age 65.5 years, 45.8% female) admitted with COVID-19. Acute kidney injury occurred in 27.1%, and 25.4% died. Ratio < 0.6 was seen in 38.6%, associated with female sex, diabetes, hypothyroidism, and higher age. Ratio < 0.6 group had mortality notably higher − 40.9% vs. 16.2% and more cases of acute kidney injury (40.9% vs. 18.9%). Cystatin C showed strong associations with the ratio < 0.6 compared to creatinine. Urea levels and urea/creatinine ratio were higher in the ratio < 0.6 group. After excluding acute kidney injury patients, ratio < 0.6 remained associated with higher cystatin C and urea levels. Other biomarkers linked to a kidney injury as NGAL, and proteinuria did not differ. CONCLUSION: We prove that reduced ratio is common in hospitalized patients with SARS-CoV-2 pneumonia and is associated with increased mortality during hospitalization. Factors that influence this ratio are complex and, in addition to the possible shrinkage of pores, other conditions such as thickening of glomerular basal membrane, comorbidities, prerenal kidney failure and others may play an important role and should be addressed when diagnosing SPS. We highlight the need for additional diagnostic criteria for SPS and larger studies to better understand its implications in acute COVID-19 settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03315-x. |
format | Online Article Text |
id | pubmed-10500727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105007272023-09-15 eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study Avotins, Lauris Kroica, Juta Petersons, Aivars Zentina, Dace Kravale, Zaiga Saulite, Anna Racenis, Karlis BMC Nephrol Research BACKGROUND: Shrunken Pore Syndrome (SPS), defined as a reduced ratio between two estimated filtration rates (based on cystatin C and creatinine) is an increasingly recognized risk factor for long-term mortality. Although some patients with other conditions might be erroneously identified as SPS. Our aim was to bring the focus on possible pathophysiologic mechanisms influencing the ratio in the setting of SARS-CoV-2 pneumonia and acute kidney injury. METHODS: A single-centered prospective cohort study was conducted to investigate biomarkers in symptomatic COVID-19 pneumonia patients admitted to a hospital in Latvia. Nineteen biomarkers were measured in blood and three in urine samples. Associations were sought between these biomarkers, chronic diseases and the estimated GFR(cystatinC)/eGFR(creatinine) ratio < 0.6, mortality rates, and acute kidney injury development. Data analysis was performed using SPSS Statistics, with significance set at p < 0.05. RESULTS: We included 59 patients (average age 65.5 years, 45.8% female) admitted with COVID-19. Acute kidney injury occurred in 27.1%, and 25.4% died. Ratio < 0.6 was seen in 38.6%, associated with female sex, diabetes, hypothyroidism, and higher age. Ratio < 0.6 group had mortality notably higher − 40.9% vs. 16.2% and more cases of acute kidney injury (40.9% vs. 18.9%). Cystatin C showed strong associations with the ratio < 0.6 compared to creatinine. Urea levels and urea/creatinine ratio were higher in the ratio < 0.6 group. After excluding acute kidney injury patients, ratio < 0.6 remained associated with higher cystatin C and urea levels. Other biomarkers linked to a kidney injury as NGAL, and proteinuria did not differ. CONCLUSION: We prove that reduced ratio is common in hospitalized patients with SARS-CoV-2 pneumonia and is associated with increased mortality during hospitalization. Factors that influence this ratio are complex and, in addition to the possible shrinkage of pores, other conditions such as thickening of glomerular basal membrane, comorbidities, prerenal kidney failure and others may play an important role and should be addressed when diagnosing SPS. We highlight the need for additional diagnostic criteria for SPS and larger studies to better understand its implications in acute COVID-19 settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-023-03315-x. BioMed Central 2023-09-13 /pmc/articles/PMC10500727/ /pubmed/37704948 http://dx.doi.org/10.1186/s12882-023-03315-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Avotins, Lauris Kroica, Juta Petersons, Aivars Zentina, Dace Kravale, Zaiga Saulite, Anna Racenis, Karlis eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study |
title | eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study |
title_full | eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study |
title_fullStr | eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study |
title_full_unstemmed | eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study |
title_short | eGFR(cystatinC)/eGFR(creatinine) ratio < 0.6 in patients with SARS-CoV-2 pneumonia: a prospective cohort study |
title_sort | egfr(cystatinc)/egfr(creatinine) ratio < 0.6 in patients with sars-cov-2 pneumonia: a prospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500727/ https://www.ncbi.nlm.nih.gov/pubmed/37704948 http://dx.doi.org/10.1186/s12882-023-03315-x |
work_keys_str_mv | AT avotinslauris egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy AT kroicajuta egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy AT petersonsaivars egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy AT zentinadace egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy AT kravalezaiga egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy AT sauliteanna egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy AT raceniskarlis egfrcystatincegfrcreatinineratio06inpatientswithsarscov2pneumoniaaprospectivecohortstudy |